AstraZeneca PLC
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Cash and cash equivalents: $5,711M in FY2025, up 4.1% from a year earlier.
Latest, FY2025
5,711
Period ended Dec 31, 2025
Change on a year earlier
+4.1%
5,488 in FY2024
History
6 years
Since FY2020
Sources
6
Documents cited below
Where the FY2025 figure comes from
“|| Cash and cash equivalents | 5,711 | 5,488”
Source: Form 6-K FY2025Q4 Earnings Release ↗
Reported in Form 6-K / 20-F Net Debt Table.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Cash and cash equivalents ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 5,711 | +4.1% | Form 6-K FY2025Q4 Earnings Release ↗ |
| FY2024 | Dec 31, 2024 | 5,488 | -6.0% | Form 6-K FY2024Q4 Earnings Release ↗ |
| FY2023 | Dec 31, 2023 | 5,840 | -5.3% | Form 6-K FY2023Q4 Earnings Release ↗ |
| FY2022 | Dec 31, 2022 | 6,166 | -2.6% | Form 6-K FY2022Q4 Earnings Release ↗ |
| FY2021 | Dec 31, 2021 | 6,329 | -19.2% | Form 6-K FY2021Q4 Earnings Release ↗ |
| FY2020 | Dec 31, 2020 | 7,832 | – | Form 6-K FY2020Q4 Earnings Release ↗ |
Cite this data
StockData. (2026). AstraZeneca Cash and cash equivalents ($M), annual FY2020–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/nd-cash-equiv
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.